Ablynx has signed a collaboration agreement with Centocor R&D, Inc. under which the companies will perform research funded by Centocor. Applying the unique properties of Nanobodies, the two companies will work jointly on novel approaches for administration and delivery of Nanobody-based therapeutics. The financial terms of the collaboration are not disclosed. Nanobodies are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirab...